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Abstract
Prostate cancer mortality projections at the na-
tionwide and regional levels to the year 2025 are 
carried out in this ecological study that is based 
on an analysis of Brazilian trends between 1996 
and 2010. The predictions were made for the pe-
riod 2011-2025 utilizing the Nordpred program 
based on the period of 1996-2010, using the age-
period-cohort model. A significant increase was 
observed in the Brazilian rates between 1996 and 
2006, followed by a non-significant decrease. The 
projections indicate a decrease in rates at a na-
tional level as well as for the Central, South and 
Southeast regions. Increases are expected for the 
North and Northeast regions. In conclusion, a 
reduction in the mortality rates for prostate can-
cer in Brazil is expected to the year 2025, as well 
as for the Central, South and Southeast regions. 
However, an increase in the absolute number of 
deaths in all regions is expected due to the an-
ticipated aging of the population.
Prostatic Neoplasms; Mortality; Population 
Studies in Public Health
Resumo
Este estudo ecológico realiza projeções de mor-
talidade por câncer de próstata no Brasil e suas 
regiões até o ano 2025, com base nas tendências 
observadas no período de 1996 a 2010. As proje-
ções foram realizadas para o período 2011-2025 
mediante o programa Nordpred, baseado no pe-
ríodo 1996-2010, usando o modelo idade-perío-
do-coorte. Observou-se um aumento significati-
vo das taxas no Brasil entre 1996 e 2006, seguido 
de um descenso não significativo. As projeções 
indicam uma diminuição das taxas em nível 
nacional e nas regiões Centro-oeste, Sul e Sudes-
te, enquanto nas regiões Norte e Nordeste se es-
pera um incremento das taxas. É esperada uma 
redução das taxas de mortalidade por câncer de 
próstata até o ano 2025 no Brasil em conjunto, 
assim como nas regiões Centro-oeste, e Sul e Su-
deste, e um incremento nas regiões Norte e Nor-
deste. Contudo, prevê-se um aumento do núme-
ro absoluto de mortes pela doença em todas as 
regiões devido ao envelhecimento populacional 
previsto no país.
Neoplasias da Próstata; Mortalidade; Estudos 
Populacionais em Saúde Pública
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Introduction
Prostate cancer is considered globally to be the 
most prevalent and the sixth most mortal type 
of cancer in men. In Brazil, prostate cancer is 
the most common type of cancer in men and, 
in terms of the number of deaths, occupies sec-
ond position, after lung cancer. The incidence 
rate is approximately 50 per 100,000 inhabitants, 
with more than 40,000 cases diagnosed annually. 
14,500 deaths by prostate cancer are registered 
every year in Brazil, with rates of 16 deaths per 
100,000 inhabitants per year, slightly fewer than 
lung cancer 1.
It has been observed that prostate cancer 
mortality rates have not increased at the same 
rate as incidence rates, probably due to improve-
ments in treatment associated with diagnosis 
measures 2. The prostate-specific antigen (PSA) 
test was responsible, principally after the 1980s, 
for causing increases in incidence and survival 
rates for prostate cancer, as a consequence of 
early diagnosis 3,4. However, the prevalence of 
PSA testing is relatively low in less developed 
countries, where Western influenced lifestyles 
have caused increases in prostate cancer rates 5. 
In the case of Brazil, the adjusted mortality rates 
increased by approximately 70% from the early 
1980s to the start of the 21st century 6.
The International Agency for Research on 
Cancer (IARC) predicts that the number of deaths 
by prostate cancer in Brazil will almost double by 
the year 2025 1. However, these projections are 
limited, as there are no age- or region- specif-
ic data available. The detailed study presented 
herein is very important in a country with a high 
proportion of inequalities and profound region-
al differences such as Brazil. Furthermore, trend 
analysis and cancer mortality projections are 
very useful for planned interventions such as 
screening programs and therapy advances, as 
well as to quantify the probable burden of cancer 
in the future.
The objective of this study is to carry out pro-
jections of prostate cancer mortality in Brazil and 
its regions until the year 2025, based on the trend 
analysis for the period 1996-2010.
Method
This is an ecological study for which the data 
were obtained from the Brazilian Ministry of 
Health web page (Departamento de Informáti-
ca do SUS. Informações de Saúde. Estatísticas 
Vitais. http://www2.datasus.gov.br/DATASUS/
index.php?area=0205, accessed on 02/Jul/2013) 
along with population data from 1996 to 2010. 
All deaths registered as prostate cancer (ICD-10 
code: C61) were included in the analysis. The 
quality of death certificates is comparable to 
those of developed countries, and the propor-
tion of ill-defined death causes is lower than 
13% for the overall country and lower than 6% 
for the capital cities (Global Health Observatory 
Data Repository, World Health Organization. De-
mographic and Socioeconomic Statistics: Census 
and Civil Registration Coverage. Data by Country. 
http://apps.who.int/gho/data/node.main.121, 
accessed on 23/Apr/2014) 7.
Analyses of mortality and predictions were 
performed by calculating crude and adjusted 
rates, expressed per 100,000 persons per year. 
The adjusted mortality rates were calculated 
by the direct method using the world standard 
population as reference for Brazil and its five re-
gions (North, Northeast, Central, Southeast, and 
South). Adjusted rates for each year were calcu-
lated to study trends using the Joinpoint Regres-
sion Program (National Cancer Institute, Bethes-
da, USA). Crude rates were calculated, as well as 
the confidence intervals for the adjusted rates, 
to a confidence level of 95%. The objective was 
to determine whether the estimated trends were 
statistically significant or not. Joinpoint analy-
sis identifies the moment in which changes in 
trends occur and calculates the annual percent-
age change (APC) in each segment. The analysis 
starts with a minimum number of joinpoints and 
compares whether one or more are significant 
to the model 8. Birth-cohort analysis was car-
ried out graphically and dividing data in five- 
year periods.
Predictions were made for the periods 2011-
2015, 2016-2020 and 2021-2025, using the age-
period-cohort model of the Nordpred program 
(Cancer Registry of Norway, Oslo, Norway), 
written in the statistical program R. Data were 
pooled into five-year blocks and the age group 
limit considered for analysis was the one with 
more than 10 cases in the combined periods. 
Predictions were made by geographical region 
and the pooled results will be referred to as to-
tal presented by age ranges (0-54, 55-74 and ≥ 75 
years of age). As prostate cancer is more common 
in individuals over the age of 55, age groups were 
employed following Moller et al. 9. Changes in 
the annual number of cases of the last predicted 
period relating to the last observed period (2006-
2010) were calculated by geographical region. 
The proportion of this change occurring in terms 
of risk or change in population (size and popu-
lation structure) was also calculated. These two 
components can be different from zero and pres-
ent a positive or negative direction. The calcula-
tion can be expressed as follows 9,10:
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Δ tot = Δ risk + Δ pop = (Nfff – Noff) + (Noff – Nooo)
where: Δ tot = total change, Δ risk = change in func-
tion of risk, Δ pop = change in function of popu-
lation, Nooo = number of observed cases, Nfff = 
number of predicted cases and Noff = number of 
expected cases when increasing the mortality 
rates in the observed period.
The Brazilian and regional population used 
in the projections were obtained from the web-
site of the Brazilian Institute for Statistics and 
Geography (IBGE) 11.
Results
In the period 1996-2010, 139,349 deaths were reg-
istered in the Brazilian mortality database as be-
ing from prostate cancer. The Joinpoint analysis 
shows an initial increase in mortality rates, fol-
lowed by a stable plateau after the year 2006. The 
same trend is found by region, with an exception 
for the North region, where significant increases 
were verified for the entire period. In the remain-
ing regions, the initial increase occurred until the 
years 2005 and 2006, followed by a decrease in 
rates. However, the APC were not statistically sig-
nificant in the second segment (Table 1).
Trend analysis for mortality by birth cohort 
shows an increment in rates for individuals in the 
age groups of 75-79 and 80-84 years of age, with 
a change in trends and stability for younger co-
horts starting from 1933 (Figure 1).
Table 2 presents the total number of deaths 
and death by age group, along with rates that 
are adjusted to the world population, during the 
observed and projected periods, for Brazil and 
its geographic regions. For the projected period 
(2011-2025) an increase in the absolute number 
of deaths is predicted, reaching a total number 
of 236,086 cases. During the most recent period 
under observation (2006-2010), 59,647 deaths 
were registered, and 91,420 cases are expected 
for the last projected period (2021-2025). When 
comparing the most recent period with the last 
projected period, an increase of 53.3% is pre-
dicted in the number of deaths, with 60% of these 
being as a result of population changes, and a 
reduction of 6.8% is also expected in death risk 
by prostate cancer.
Figure 2 shows a comparison of prostate can-
cer mortality rates: observed adjusted versus pro-
jected for the five regions of Brazil. The predicted 
increase can be observed in the adjusted mor-
tality rates for the North and Northeast regions, 
attributed both to increases in risk as well as to 
population changes. Decreases are predicted 
for the remaining regions (South, Southeast and 
Central) due to reductions in risk.
Discussion
From 1996 onwards, a significant increase in 
Brazilian prostate cancer mortality rates was ob-
served, followed by a slight decrease in the period 
after 2006. The projections of this study indicate 
decreases in mortality rates from prostate cancer 
in Brazil, as well as in the South, Southeast and 
Central regions, until the year 2025. In contrast, 
an increase is predicted in the rates of less devel-
oped regions of the country, in the North and par-
ticularly in the Northeast region. Nevertheless, it 
must be mentioned that it is expected that the 
absolute number of deaths from prostate cancer 
increases in all regions due to the population ag-
ing process in Brazil. This increase in mortality is 
predicted to be smooth in the South and South-
east regions, as a consequence of the reduction 
in risk or increased effectiveness of early diag-
nosis, while for the North and Northeast regions 
Table 1
Number of deaths, annual percentage change (APC), 95% confidence intervals (95%CI) and joinpoint year by geographical 
region.
Geographical region Deaths APC1 95%CI Joinpoint APC2 95%CI
North 5,106 3.9 * 2.9; 4.8 - - -
Northeast 31,633 7.3 * 5.5; 9.0 2006 -2.9 -26.4; 28.1
Central 8,742 2.2 -0.2; 4.8 2006 -2.7 -8.4; 3.3
Southeast 67,680 0.9 -0.8; 2.6 2005 -4.1 -7.9; 0.0
South 26,191 1.9 -0.1; 3.9 2005 -4.1 -8.7; 0.7
Brazil 139,349 2.5 * 1.4; 3.6 2006 -2.3 -6.6; 2.1
* Statistically significant values (p-value < 0.005).
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Figure 1
Mortality trends by birth cohort.
Table 2
Observed and predicted average number of deaths by age and crude rate (CR), world age-standardized rates (ASW) and 95% confidence interval  
(95%CI) in Brazil.
Geographic region Observed Predicted
1996-2000 2001-2005 2006-2010 2011-2015 2016-2020 2021-2025
North
Age (years)
0-54 53 63 59 133 178 215
55-74 478 686 967 1,827 2,339 2,815
≥ 75 524 809 1,462 2,978 3,876 4,831
Total 1,055 1,558 2,488 4,937 6,393 7,861
CR 3.4 4.3 6.4 12.3 15.4 18.5
ASW (95%CI) 7.1 (6.0; 8.0) 8.2 (7.2; 9.1) 10.1 (9.1; 10.9) 11.9 (11.1; 12.6) 12.9 (12.1; 13.6) 13.2 (12.5; 13.9)
Northeast
Age (years)
0-54 192 193 299 550 718 1,067
55-74 2,613 3,322 5,292 8,471 11,462 13,510
≥ 75 3,345 5,753 10,620 15,771 22,368 28,788
Total 6,150 9,268 16,211 24,792 34,548 43,365
CR 5.4 7.6 12.4 18.0 25.0 30.0
ASW (95%CI) 6.9 (6.5; 7.3) 8.7 (8.3; 9.2) 12.9 (12.4; 13.4) 17.5 (16.9; 17.9) 20.3 (19.8; 20.8) 21.2 (20.8; 21.7)
Central
Age (years)
0-54 61 61 88 100 102 103
55-74 968 1,201 1,514 1,805 2,086 2,482
≥ 75 1,081 1,570 2,915 2,865 3,243 3,778
Total 2,110 2,832 3,797 4,770 5,431 6,362
CR 7.6 9.1 11.1 13.4 14.8 16.9
ASW (95%CI) 14.0 (12.6; 15.3) 14.7 (13.4; 16.0) 13.7 (12.7; 14.7) 12.9 (12.1; 13.8) 12.3 (11.6; 13.1) 12.1 (11.3; 12.7)
(continues)
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Table 2 (continued)
Geographic region Observed Predicted
1996-2000 2001-2005 2006-2010 2011-2015 2016-2020 2021-2025
Southeast
Age (years)
0-54 408 479 543 419 436 398
55-74 8,111 9,205 9,976 8,897 9,577 11,031
≥ 75 9,792 13,089 16,075 14,742 16,117 18,292
Total 18,311 22,773 26,594 24,059 26,131 29,720
CR 10.8 12.3 13.6 11.7 12.4 13.7
ASW (95%CI) 14.7 (14.2; 12.2) 15.0 (14.5; 15.4) 12.9 (12.5; 13.3) 11.3 (10.9; 11.6) 10.2 (9.9; 10.2) 9.7 (9.4; 9.9)
South
Age (years)
0-54 157 168 195 141 120 109
55-74 3,019 3,635 4,024 3,357 3,578 4,008
≥ 75 3,713 4,944 6,332 6,197 6,853 7,689
Total 6,889 8,747 10,551 9,694 10,550 11,805
CR 11.5 13.6 15.5 13.7 14.4 15.7
ASW (95%CI) 15.9 (15.0; 16.8) 17.1 (16.2; 17.8) 14.8 (14.1; 15.4) 13.0 (12.3; 13.6) 11.8 (11.2; 12.3) 11.0 (10.5; 11.5)
Brazil
Age (years)
0-54 871 964 1,184 1,183 1,159 1,179
55-74 15,189 18,040 21,773 23,893 27,720 32,050
≥ 75 18,458 26,171 36,690 41,457 49,256 58,191
Total 34,518 45,184 59,647 66,533 78,134 91,420
CR 8.6 10.3 12.8 13.7 15.6 17.8
ASW (95%CI) 12.0 (11.7; 12.3) 13.0 (12.7; 13.3) 13.1 (12.8; 13.3) 13.1 (12.8; 13.3) 12.8 (12.6; 12.9) 12.5 (12.3; 12.5)
the changes in risk and population may almost 
double the number of deaths by the year 2025.
When analyzing cancer projections two situ-
ations must be distinguished, which could influ-
ence the number of deaths: changes in death risk 
by cancer and changes in the exposed popula-
tion itself. Population changes can occur due to 
population increases and structural changes 12,13. 
In Brazil, the global phenomenon of population 
aging is picking up speed, due to the quite steep 
decline in fecundity rates, decreases in mortality, 
and increases in life expectancy 13. The number 
of individuals over the age of 60 is expected to 
increase by approximately 60% from the period 
2006-2010 to 2021-2025 11. This trend will par-
ticularly affect the case of prostate cancer, as age 
is known to be one of the main risk factors as-
sociated with incidence and mortality from this 
disease 14,15.
Regarding cancer mortality rates, there are 
three factors that could exert an influence: chan-
ges in risk factors for the development of the dis-
ease, screening programs and advances in treat-
ment 16. Currently it is known that non-modifi-
able risk factors, such as family-genetic factors 
and especially age, play an important role in 
the development of prostate cancer. However, 
these factors do not affect the analysis presented 
herein because this study analyzed age-adjusted 
rates and at a collective level, where there is a 
low influence of family-genetic factors. Regard-
ing modifiable risk factors, such as obesity and 
the consumption of tobacco and alcohol, which 
have already been established for other types 
of cancer, the association remains little known 
for prostate cancer 15. For this reason, it is not 
possible to explain the influence of these factors 
in the regional differences in mortality rates en-
countered herein.
An explanation for the change from an initial 
increase to the stable plateau observed in this 
study could be a result of the improvements in 
screening programs and therapeutic measures 
in the more developed regions of Brazil. Prostate 
cancer screening has not been systematically 
applied in Brazil, and there is an inequality in 
the availability of diagnostic tests with regard to 
socio-demographic and socioeconomic levels. In 
this way, the difficulty of accessing diagnosis and 
treatment services for individuals in conditions 
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Figure 2
World age-standardized rates (ASW), changes in numbers of deaths (n), total change (change), relative change due to risk (risk) 
and changed population (pop), between 2006-2010 (observed) and 2021-2025 (predicted) of prostate cancer  
mortality in Brazil.
of poverty could explain the higher prostate can-
cer mortality rates observed in the low stratum 17. 
This difficulty in accessing diagnosis services 
seems to occur with a greater frequency in the 
North and Northeast regions, where the projec-
tions of this study reveal increasing mortality 
rates. Therefore some studies show that prostate 
cancer tracking is less prevalent in men under 
the age of 70, with less years of schooling, and of 
low-income 17,18. An ecological study carried out 
in Brazil has found that approximately 57% of the 
individuals with a higher education level related 
diagnostic practices such as digital rectal exam 
or PSA, while for individuals with less years of 
schooling the percentage was only 35% 17.
A pronounced inequity between the regions 
of Brazil remains regarding access to prostate 
cancer treatment. The different mortality trends 
encountered herein can be partially attributed 
to that fact that therapeutic services are much 
more limited in less developed regions of Bra-
zil (the North and Northeast). In municipalities 
in the interior of these areas, Silva et al. 19 have 
found increases in cancer rates twice as high as 
those registered in capital cities of the country. 
In these regions, low-income individuals that use 
the public health system occasionally suffer as a 
result of late diagnoses, precariousness of servi-
ces and tardiness in beginning treatment, which 
compromises prognostics. In addition, a much 
higher offer of chemotherapy and radiotherapy 
services is concentrated in the South and South-
east regions, where there is a higher proportion 
of individuals who can afford private health 
plans 18,19.
The evolution observed in the rates of this 
study for the more developed regions of Brazil is 
similar to that found in the majority of European 
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countries and the USA. In these countries, mor-
tality rates have declined during the last two dec-
ades, probably due to early diagnoses facilitated 
by the PSA testing and improvements in prostate 
cancer treatment 4,5,20. Such a trend has also been 
observed in other South American countries, as 
is the case of Chile and Argentina. Nevertheless, it 
is worth highlighting that in these countries, the 
adjusted rates are higher than the Brazilian rates, 
with changes occurring earlier, at the end of the 
1990s (International Agency for Research on 
Cancer; World Health Organization. Cancer Mor-
tality Database. http://www-dep.iarc.fr/whodb/
whodb.htm, accessed on 30/Jul/2013) 21,22.
As a limitation of this study, the period for 
which the projections apply – just 15 years – is 
short. Regarding the national registry of deaths 
by cancer in Brazil, it must be mentioned that 
in the past there were issues with data reliability, 
particularly in the North and Northeast regions, 
but improvements have been made since the 
2000s 6. Cancer projections must be considered 
with caution, as the actual diagnosis and treat-
ment conditions might change in the future, and 
consequently modify the mortality trends. How-
ever, the methods currently used have certified 
validity and some authors point to small differ-
ences of between 10 and 20% in estimations 2.
In conclusion, an initial increase in prostate 
cancer mortality rates was herein demonstrat-
ed, followed by a slight decrease in rates that is 
predicted to take place until the year 2025 in the 
entire country. However, in the North and North-
east regions increases in mortality are expected, 
attributed to changes in risk and the aging of the 
population. The results of the projections pre-
sented herein clearly show the inequities present 
in prostate cancer mortality rates per geograph-
ic region, which must be considered for the de-
velopment of public policies and for the planning 
of health services.
Resumen
Este estudio ecológico presenta proyecciones de mor-
talidad por cáncer de próstata en Brasil y sus regiones 
para el año 2025, en base a las tendencias observadas 
en el período 1996-2010. Las proyecciones se realiza-
ron para el período 2011-2025, mediante el programa 
NORDPRED, con base en el período 1996-2010, utili-
zando el modelo edad-período-cohorte. Hubo un au-
mento significativo en las tasas en Brasil entre 1996 y 
2006, seguido de una disminución no significativa. Las 
proyecciones indican una disminución de las tasas, 
tanto a nivel nacional, como en las regiones Centro-
oeste, Sur y Sudeste, mientras que en las regiones Nor-
te y Nordeste se espera un incremento de las tasas. Se 
prevé una disminución de la mortalidad por cáncer de 
próstata para el año 2025 en Brasil en su conjunto, así 
como en las regiones Centro-oeste, Sur y Sudeste, y un 
aumento en las regiones Norte y Nordeste. Sin embargo, 
se espera un aumento del número absoluto de muertes 
de la enfermedad en todas las regiones, debido al enve-
jecimiento de la población previsto en el país.
Neoplasias de la Próstata; Mortalidad; Estudios Pobla-
cionales en Salud Pública
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